1ST-104 / 1ST Bio, SK Bio - LARVOL DELTA

SK Biopharmaceuticals Introduces First Biotherapeutics' Parkinson's Disease Drug Candidate (The Asia Business Daily) - "On September 17, SK Biopharmaceuticals announced that it had signed a license agreement with First Biotherapeutics, securing the exclusive global development and commercialization rights for the Parkinson's disease treatment candidate, as well as a strategic equity investment deal worth 3 billion won...The license agreement consists of a contract payment of 2.5 billion won, milestone payments of up to 72.5 billion won based on research, development, and commercialization stages, and additional milestone payments of up to USD 260 million (approximately 355.8 billion won) according to net sales...The drug candidate in question is an orally-administered small-molecule compound that simultaneously inhibits LRRK2 and c-Abl...Based on the research outcomes, SK Biopharmaceuticals plans to review further development for future Investigational New Drug (IND) application."

Licensing / partnership • Parkinson's Disease